The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
MPN Workshop of the Carolinas 2024 | Origins and treatment options for anemia in myelofibrosis
Ruben Mesa, MD, Levine Cancer Institute, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston Salem, NC, discusses the origins and treatment options for anemia in myelofibrosis (MF), highlighting the role of the JAK2 inhibitors momelotinib and pacritinib, as well as the promise of additional agents including luspatercept. Looking toward the future, Dr Mesa suggests that therapies with a more significant impact on the disease may have the potential to favorably impact anemia. This interview took place at the 1st Annual MPN Workshop of the Carolinas in Asheville, NC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research Funding: Promedior, Incyte, Genetech, Abbvie, Samus, Celgene, Constellation, CTI BioPharma.- a Sobi Company, Mays Cancer Center, NCI;
Consultancy: Constellation, LaJolla Pharma, Sierra Onc, Novartis.
